bleomycin (blenoxane) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Bleomycin is a mixture of cytotoxic glycopeptide antibiotics isolated from a strain of Streptomyces verticillus. Bleomycin has antitumor activity. Bleomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Bleomycin has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2. The antibiotic antitumor drugs are cell cycle-nonspecific except for Bleomycin (which has major effects in G2 and M phases).   NCATS

Chemistry

  • SMILES: C[C@@H](O)[C@H](NC(=O)[C@@H](C)[C@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1nc(nc(N)c1C)[C@H](CC(=O)N)NC[C@H](N)C(=O)N)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2O[C@H]3O[C@H](CO)[C@@H](O)[C@H](OC(=O)N)[C@@H]3O)c4c[nH]cn4)C(=O)NCCc5nc(cs5)c6nc(cs6)C(=O)NCCC[S+](C)C.OS(=O)(=O)O
  • InChIKey: WUIABRMSWOKTOF-OYALTWQYSA-O
  • Mol. Mass: 1513.66
  • ALogP: Missing data
  • ChEMBL Molecules:
    bleomycin sulfate  
    None  
    bleomycin  
    None  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$2.8333 - $38.5600

Australia

$31.0120
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

blenoxane | bleocin | bleo-kyowa | bleomicin | bleomicina | bleomycin | bleomycin a2 | bleomycin a2 sulfate | bleomycine | bleomycin hcl | bleomycin hydrochloride | bleomycins | bleomycin sulfate | bleomycin (sulfate) | bleomycinum | blm

Organizations (190)

Research & Development (181)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (51)

Approved Indications (7)


 

Carcinoma, Squamous Cell

Choriocarcinoma (approved 1975)

Hodgkin Disease (approved 1973)

Lymphoma, Non-Hodgkin (approved 1973)

Pleural Effusion, Malignant

Teratocarcinoma (approved 1975)

Testicular Neoplasms (approved 1973)

Experimental Indications - Clinical Trial Phases 1-4 (47)


 

Acne Vulgaris (Phase 2)

Aging (Phase 2)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 2)

Capillaries (Phase 2)

Cardiotoxicity (Phase 3)

Cicatrix (Phase 4)

Colorectal Neoplasms (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Electrochemotherapy (Phase 2)

Genital Neoplasms, Female (Phase 2)

Germinoma (Phase 2)

Head and Neck Neoplasms (Phase 3)

HIV (Phase 1)

HIV Infections (Phase 3)

Hodgkin Disease (Phase 4)

Keloid (Phase 4)

Liver Neoplasms (Phase 1/Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Large-Cell, Immunoblastic (Phase 3)

Lymphoma, Non-Hodgkin (Phase 3)

Lymphoma, T-Cell, Peripheral (Phase 3)

Mediastinal Neoplasms (Phase 3)

Melanoma (Phase 1)

Multiple Myeloma (Phase 2)

Mycoses (Phase 1)

Neoadjuvant Therapy (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 3)

Neoplasms, Germ Cell and Embryonal (Phase 3)

Ovarian Diseases (Phase 2)

Ovarian Neoplasms (Phase 3)

Pancreatic Neoplasms (Phase 1)

Sarcoma, Kaposi (Phase 3)

Sclerosis (Phase 2)

Seminoma (Phase 3)

Skin Neoplasms (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Stomach Neoplasms (Phase 1)

Teratoma (Phase 3)

Testicular Neoplasms (Phase 3)

Uterine Cervical Neoplasms (Phase 3)

Vascular Malformations (Phase 2)

Venous Cutdown (Phase 4)

Warts (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 173
  • # of Trial Organizations: 181

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue